HLS Therapeutics Inc. (HLS) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Hls Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.959 -- 00:00:04.564 Good morning and welcome to the Q2 2025 00:00:04.564 -- 00:00:08.390 Financial Results Conference Call for HLS Therapeutics. 00:00:08.390 -- 00:00:12.876 At this point, I would like to turn the call over to David Mason, Investor Relations, 00:00:12.876 -- 00:00:15.878 for the introductory remarks. 00:00:16.301 -- 00:00:19.826 Good morning, everyone, and thank you for joining us today. 00:00:19.826 -- 00:00:25.114 With me on the call is Craig Millian, Chief Executive Officer, John Hanna, 00:00:25.114 -- 00:00:30.288 Chief Financial Officer, and Brian Walsh, Chief Commercial Officer. 00:00:30.288 -- 00:00:34.734 Earlier this morning, we issued a news release announcing our financial results for the 00:00:34.734 -- 00:00:38.736 three and six months ended June 30, 2025. 00:00:39.119 -- 00:00:43.825 This news release, along with our MD&A and financial statements, is available on our 00:00:43.825 -- 00:00:47.390 website and on CDAR+. Please 00:00:47.390 -- 00:00:52.416 note that slides accompanying today's call can be viewed by the webcast, a 00:00:52.416 -- 00:00:57.422 link to which is available in our earnings press release and at our website 00:00:57.422 -- 00:01:00.764 on the events and presentations page. 00:01:00.764 -- 00:01:04.949 Certain matters discussed in today's conference call or answers that may be given to 00:01:04.949 -- 00:01:08.773 questions could constitute forward-looking statements. 00:01:08.773 -- 00:01:12.798 Actual results could differ materially from those anticipated. 00:01:12.798 -- 00:01:17.043 Risk factors that could affect results are detailed in the company's annual information 00:01:17.043 -- 00:01:20.725 form, which has been filed on CDAR+. 00:01:20.847 -- 00:01:24.171 During the call, we will refer to ...